Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hypercholesterolemic Patients With Coronary Artery Disease
Public ClinicalTrials.gov record NCT00706849. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of ISIS 301012 as Add-on Therapy in Heterozygous Familial Hypercholesterolemia Subjects With Coronary Artery Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine whether mipomersen safely and effectively lowers low-density lipoprotein cholesterol (LDL-C) in patients with Heterozygous Familial Hypercholesterolemia (HeFH) and coronary artery disease (CAD) who are already on a stable dose of other lipid-lowering agents (including maximally tolerated statin therapy).
Study identification
- NCT ID
- NCT00706849
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 124 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2008 (Type not available)
- Primary completion
- Dec 2009 (Actual)
- Completion
- May 2010 (Actual)
- Last update posted
- Sep 9, 2016
2008 – 2010
United States locations
- U.S. sites
- 37
- U.S. states
- 20
- U.S. cities
- 34
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | La Jolla | California | 92093 | — |
| Not listed | Los Angeles | California | 90048 | — |
| Not listed | Mission Viejo | California | 92691 | — |
| Not listed | Newport Beach | California | 92260 | — |
| Not listed | Santa Ana | California | 92705 | — |
| Not listed | Thousand Oaks | California | 91360 | — |
| Not listed | Bridgeport | Connecticut | 06606 | — |
| Not listed | Melbourne | Florida | 32901 | — |
| Not listed | Pensacola | Florida | 32514 | — |
| Not listed | Chicago | Illinois | 60610 | — |
| Not listed | Naperville | Illinois | 60540 | — |
| Not listed | Kansas City | Kansas | 66160 | — |
| Not listed | Biddeford | Maine | 04005 | — |
| Not listed | Scarborough | Maine | 04074 | — |
| Not listed | Boston | Massachusetts | 02114 | — |
| Not listed | Ann Arbor | Michigan | 48109-5853 | — |
| Not listed | St Louis | Missouri | 63110 | — |
| Not listed | Las Vegas | Nevada | 89144 | — |
| Not listed | Concord | New Hampshire | 03301 | — |
| Not listed | New York | New York | 10032 | — |
| The Rogosin Institute Comprehensive Lipid Control Center | New York | New York | 10065 | — |
| Not listed | Charlotte | North Carolina | 28204 | — |
| Not listed | Charlotte | North Carolina | 28211 | — |
| Not listed | Durham | North Carolina | 27710 | — |
| Not listed | Cincinnati | Ohio | 45212 | — |
| ResEvo, LLC | Cuyahoga Falls | Ohio | 44223 | — |
| Not listed | Franklin | Ohio | 45005 | — |
| Not listed | Oklahoma City | Oklahoma | 73120 | — |
| Not listed | Portland | Oregon | 97239 | — |
| Not listed | Nashville | Tennessee | 37232 | — |
| Not listed | Dallas | Texas | 75220 | — |
| Not listed | Dallas | Texas | 75226 | — |
| Not listed | Grapevine | Texas | 76051 | — |
| Not listed | Houston | Texas | 77093 | — |
| Not listed | San Antonio | Texas | 78229 | — |
| Not listed | Salt Lake City | Utah | 84108 | — |
| Not listed | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00706849, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 9, 2016 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00706849 live on ClinicalTrials.gov.